From the publishers of JADPRO

Acute Lymphoblastic Leukemia Resource Center

Advertisement

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy

Last Updated: Wednesday, April 23, 2025

This study investigated CART22-65s, a novel CD22-targeted CAR T-cell therapy, for children and adults with relapsed B-ALL after CD19 therapy. In 19 infused patients, the complete remission rate was 74%. The therapy demonstrated a favorable safety profile, suggesting its potential for treating this highly refractory leukemia.

Journal for Immunotherapy of Cancer
Advertisement
News & Literature Highlights

Discover Oncology

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: A case series and literature review

Frontiers in Oncology

Impact of standardized immunophenotyping and MRD monitoring on early mortality reduction in childhood leukemia: A step towards addressing healthcare disparities in vulnerable populations from Southern Mexico

Clinical and Experimental Pediatrics

Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/ refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis

Medical Journal, Armed Forces India

Bone mineral density in childhood acute lymphoblastic leukaemia survivors and factors affecting it

Blood Advances

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Pediatrics International: Official Journal of the Japan Pediatric Society

Safety and efficacy of sedation for pediatric patients with cancer and developmental disabilities

BMC Ophthalmology

Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution

Leukemia

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial

Cancer

Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Clinical Laboratory

T-acute lymphoblastic leukemia/lymphoma manifesting as acute renal failure

Advertisement
Advertisement